Chrome Plugin Live! Redefine the way you read FinTwit 🚀 Install Now
Quote Panel
Key Metrics
Fundamentals
Relative Strength
SEQUENT.NS
Sector
Top 5 RS in Group
Symbol | Company | RS | 5-Day Perf. |
|---|---|---|---|
Forecast
Analyst rating
Last analyst upgrade/downgrade
Earnings Growth
YoY
Current
Estimates
Q3.22
N/A
-0.15
vs NA
Q4.22
N/A
-0.36
vs NA
Q1.23
N/A
-3.77
vs NA
Q2.23
N/A
-1.40
vs -0.56
Q3.23
N/A
-0.34
vs -0.15
Q4.23
N/A
-0.04
vs -0.36
Q1.24
N/A
NA
vs -3.77
Q2.24
+107%
0.1
vs -1.40
Q3.24
+138%
0.13
vs -0.34
Q4.24
+100%
NA
vs -0.04
Sales Growth
YoY
Current
Estimates
Q1.23
-4%
3.7B vs 3.8B
Q2.23
-2%
3.3B vs 3.4B
Q3.23
+2%
3.5B vs 3.4B
Q4.23
-12%
3.3B vs 3.8B
Q1.24
-1%
3.6B vs 3.7B
Q2.24
+17%
3.9B vs 3.3B
Q3.24
+7%
3.7B vs 3.5B
Q4.24
+19%
3.9B vs 3.3B
Q1.25
+4%
3.8B vs 3.6B
Q2.25
+375%
18.5B vs 3.9B
Return on Equity
QoQ
Q1.23
-13%
-0.13
vs -0.01
Q2.23
-5%
-0.05
vs -0.13
Q3.23
-1%
-0.01
vs -0.05
Q4.23
+1%
0.01
vs -0.01
Q1.24
0%
-0.00
vs 0.01
Q2.24
+1%
0.01
vs -0.00
Q3.24
+0%
0
vs 0.01
Q4.24
NA
NA
vs 0
Institutionnal Ownership
Relative Strength
SEQUENT.NS
Sector
Top 5 RS in Group
Symbol | Company | RS | 5-Day Perf. |
|---|---|---|---|
Sequent Scientific Limited engages in the animal health business worldwide. The company provides animal health active pharmaceutical ingredients (APIs) and finished dosage formulations in the areas of feed supplements, antibiotics, anthelmintics, antibacterial, anti-protozoal, nutraceuticals, nonsteroidal anti-inflammatory drugs, anti-infectives, and dermatology. It offers analytical solutions that supports API, pharmaceutical, personal care, and nutraceutical organizations, as well as provides method validation, stability, and microbiology for APIs and finished products. The company was formerly known as PI Drugs and Pharmaceuticals Limited and changed its name to Sequent Scientific Limited in October 2009. Sequent Scientific Limited was incorporated in 1985 and is headquartered in Mumbai, India. Sequent Scientific Limited operates as a subsidiary of CA Harbor Investments.
NSE
1.45Â ( 0.77%)
Relative Strenght
Volume Buzz
-50%
Earning Acce
No
Dist 52w H.
21%Quote Panel
Key Metrics
Forecast
292%2025-Revenue
1186%2025-EPS
203%2025-EBITDA
Analyst rating
Strong Sell
Sell
Buy
Neutral
Strong Buy
Price Target
NaN(-100.00%)
Number of analyst
Last analyst upgrade/downgrade
No Data Available
Fundamentals
P/E Ratio
P/S Ratio
P/B Ratio
Debt/Equity
Net Margin
EPS
How SEQUENT.NS compares to sector?